Dysphagia Knowledge Hub — 吞嚥困難知識庫
Vitamin D Deficiency and Swallowing Muscle Function
Vitamin D has long been recognised for its role in calcium homeostasis and bone mineralisation, but accumulating evidence over the past two decades has established its equally important function as a regulator of skeletal muscle physiology. For patients with dysphagia — particularly elderly individuals with sarcopenia — Vitamin D deficiency may represent a modifiable contributor to swallowing muscle weakness that is frequently overlooked in clinical management. This article reviews the prevalence of Vitamin D deficiency in Hong Kong’s elderly population, the mechanism linking Vitamin D to muscle function, the emerging evidence connecting it to sarcopenic dysphagia, supplementation protocols, monitoring parameters, and practical considerations for co-supplementation with calcium and protein.
Prevalence of Vitamin D Deficiency in HK Elderly
Vitamin D deficiency is strikingly prevalent among older adults in Hong Kong despite the city’s subtropical latitude. This apparent paradox reflects the lifestyle and built environment of HK’s elderly population: most older residents spend the majority of daylight hours indoors, and when outdoors, cultural practices (umbrella use, avoidance of direct sun) and high-SPF sunscreen application further limit cutaneous synthesis of Vitamin D3 from UVB radiation.
Epidemiological data from HK are consistent:
- Lau et al. (2001) found that 60.9% of community-dwelling Chinese women aged ≥70 had serum 25-hydroxyvitamin D [25(OH)D] <25 nmol/L (severe deficiency)
- Kung et al. (2000) reported that 54% of HK Chinese adults aged ≥65 had 25(OH)D below 30 nmol/L
- In residential care homes, where residents have even less sun exposure, prevalence of 25(OH)D <25 nmol/L may exceed 80%
The definition of Vitamin D deficiency uses the following thresholds: <25–30 nmol/L (10–12 ng/mL) = severe deficiency; 30–50 nmol/L = deficiency; 50–75 nmol/L = insufficiency; >75 nmol/L (30 ng/mL) = sufficiency. Optimal range for musculoskeletal function is generally cited as 75–125 nmol/L.
Dietary sources of Vitamin D are limited in the traditional HK Chinese diet: fatty fish (salmon, mackerel) and fortified dairy are the primary sources, but consumption of these is often low in elderly institutionalised populations.
Muscle Weakness Mechanism: Type II Fibre Atrophy
Vitamin D acts on skeletal muscle through both genomic (nuclear Vitamin D receptor-mediated gene transcription) and non-genomic (rapid intracellular signalling) pathways.
The specific finding most relevant to dysphagia is selective type II (fast-twitch) muscle fibre atrophy in Vitamin D-deficient subjects. Skeletal muscle biopsies from Vitamin D-deficient adults consistently show reduced type II fibre cross-sectional area and fibre number compared with Vitamin D-sufficient controls (Bischoff-Ferrari et al., 2004). Type II fibres are responsible for rapid, powerful muscle contractions — exactly the contraction profile required for the fast pharyngeal phase of swallowing (typically completing in under 1,000 ms).
In practical terms, Vitamin D deficiency preferentially impairs the speed and power of swallowing musculature, consistent with the clinical finding of delayed pharyngeal onset, reduced pharyngeal constriction amplitude, and impaired laryngeal elevation in sarcopenic dysphagia.
Additional mechanisms include: reduced calcium availability for muscle excitation-contraction coupling (secondary to impaired calcium absorption); impaired mitochondrial function in skeletal muscle; and reduced insulin-like growth factor-1 (IGF-1) signalling, which attenuates muscle protein synthesis.
Correlation with Sarcopenic Dysphagia
Sarcopenic dysphagia is defined as dysphagia occurring as a consequence of generalised sarcopenia (low muscle mass and function) affecting the swallowing musculature. First systematically described by Wakabayashi and Kayashita (2014), it has become an increasingly recognised subtype of dysphagia in geriatric medicine.
The link between Vitamin D deficiency and sarcopenic dysphagia operates through the broader sarcopenia pathway: Vitamin D deficiency → type II fibre atrophy and reduced muscle protein synthesis → generalised sarcopenia → swallowing muscle sarcopenia → pharyngeal phase weakness and aspiration risk.
Researchers from Japan — where geriatric dysphagia research is most advanced — have demonstrated significant correlations between 25(OH)D levels and swallowing function in elderly patients. Wakabayashi et al. (2019) found that among hospitalised elderly patients with dysphagia, serum 25(OH)D levels correlated positively with tongue pressure (a validated sarcopenic dysphagia marker), gait speed, and grip strength. The correlation between 25(OH)D and tongue pressure specifically supports the hypothesis that Vitamin D deficiency contributes to perioral and lingual muscle weakness in this population.
A prospective intervention study by Suzuki et al. (2019) reported improvement in swallowing function (measured by tongue pressure and repetitive saliva swallowing test) in malnourished elderly patients receiving Vitamin D supplementation alongside nutritional rehabilitation, compared with nutritional rehabilitation alone — suggesting an independent contribution of Vitamin D status to swallowing muscle recovery.
Supplementation: Dose and Protocol
Current guidelines from major endocrinology and nutrition bodies recommend:
For Vitamin D deficiency in elderly adults (>65 years):
- Maintenance dose: 800–2,000 IU (20–50 mcg) daily of cholecalciferol (Vitamin D3) — preferred over ergocalciferol (D2) for higher potency and longer half-life
- In severe deficiency (25(OH)D <25 nmol/L): loading dose may be used — e.g., 50,000 IU weekly for 8–12 weeks (by prescription), followed by maintenance dose
- NICE guideline NG187 (2021) recommends at least 400 IU daily for all adults in residential care; many guidelines now recommend 800–1,000 IU as the minimum effective dose for the elderly
Specific supplementation considerations for dysphagia patients:
- Standard Vitamin D3 tablets (800 IU, 1,000 IU) are small and typically IDDSI Level 7 (regular) — no texture modification needed in most patients
- For patients on IDDSI Level 4 (pureed) or below with severe swallowing impairment: liquid Vitamin D drops or solutions are available (e.g., Vigantol oil 20,000 IU/ml solution — dose measured in drops); confirm with pharmacy availability in HK
- For tube-fed patients: liquid preparations are administered via NGT or PEG directly
Combination with Calcium and Protein
Vitamin D supplementation for muscle function is most effective when combined with:
Calcium (for Vitamin D-dependent muscle function): Target calcium intake of 1,000–1,200 mg/day from dietary and supplemental sources combined. Calcium supplementation (500–1,000 mg elemental calcium/day from calcium carbonate or calcium citrate) may be required in patients with low dairy intake or malabsorption. Calcium carbonate requires gastric acid for absorption and should be taken with food; calcium citrate is acid-independent and preferred post-gastrectomy or with PPI use.
Protein (for muscle protein synthesis): Adequate protein intake is synergistic with Vitamin D for muscle preservation. The recommended target for sarcopenic elderly is 1.2–1.5 g protein/kg body weight/day, distributed across meals (at least 25–30 g per meal to stimulate muscle protein synthesis). In dysphagia patients, protein density of texture-modified meals must be deliberately calculated; protein supplementation via IDDSI-compatible fortified drinks or modules is frequently required.
Oral vs. Intramuscular Supplementation
Oral supplementation is the standard route and is effective when absorption is intact. Indications for intramuscular (IM) Vitamin D supplementation include:
- Malabsorptive conditions (short bowel syndrome, inflammatory bowel disease, bariatric surgery)
- Documented severe deficiency with non-compliance or inability to reliably take oral supplements
- Patients on PEG feeding who cannot receive oral liquids but whose tube formula does not contain adequate Vitamin D
IM cholecalciferol preparations (300,000–600,000 IU as a single injection every 3–6 months) are available by prescription in HK through private compounding pharmacies or hospital pharmacies. This provides a reliable, supervised dosing option for non-adherent patients, though monitoring is still required.
Monitoring 25(OH)D Levels
Baseline and follow-up measurement of serum 25-hydroxyvitamin D [25(OH)D] is essential to guide supplementation:
- Baseline: prior to starting supplementation in all identified high-risk patients (institutional elderly, those with limited sun exposure)
- Follow-up: 3 months after commencing supplementation (standard dose: 800–2,000 IU/day) to confirm adequacy
- Target: 75–125 nmol/L for optimal musculoskeletal function
- Safety ceiling: avoid sustained 25(OH)D >200 nmol/L (Vitamin D toxicity threshold); routine risk at 800–2,000 IU/day is negligible
In HK public hospitals, 25(OH)D is measured by HA Clinical Biochemistry laboratories; the test is available as an outpatient blood test with referral. In RCHE settings, dietitian recommendations typically include 25(OH)D testing as part of annual nutritional screening.
References
- Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. (2004). Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged 60 y. American Journal of Clinical Nutrition, 80(3), 752–758.
- Kung AW, Lee KK. (2006). Knowledge of vitamin D and perceptions and attitudes toward sunlight among community elderly in Hong Kong. BMC Public Health, 6, 226.
- Lau EM, Woo J, Lam V, et al. (2001). Vitamin D deficiency in Hong Kong elderly. Osteoporosis International, 12(11), 975–979.
- NICE. (2021). Vitamin D: supplement use in specific population groups. Public Health Guideline PH56 updated NG187. London: NICE.
- Suzuki M, Teramoto H, Watanabe T, et al. (2019). Effect of vitamin D supplementation on swallowing function in elderly patients requiring nursing care. Journal of the American Medical Directors Association, 20(12), 1615–1617.
- Wakabayashi H, Kayashita J. (2014). Prevalence of sarcopenic dysphagia in patients with dysphagia. Rinsho Eiyou (Japanese Journal of Clinical Nutrition), 125(7), 872–878.